Sai Life Sciences Share Price

Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999. Subsequently, the Company name was changed from Sai Dru Syn Laboratories Limited to Sai Life Sciences Limited dated December 16, 2003.Thereafter, the name of the Company was changed from Sai Life Sciences Limited to Sai Advantium Pharma Limited dated August 30, 2006 issued by the Registrar of Companies, Andhra Pradesh. Subsequently, the Company name was changed from Sai Advantium Pharma Limited to Sai Life Sciences Limited and a fresh Certificate of Incorporation dated May 28, 2012 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.The Company is an innovatorfocused contract research, development, and manufacturing organization (CRDMO). The Company provide endtoend services across the drug discovery, development and manufacturing value chain, for small molecule NCE to global pharmaceutical innovators companies and biotechnology firms. It possess both (a) discovery / contract research and (b) CMC / CDMO capabilities.Through the Scheme of Amalgamation, Prasad Drugs Limited was merged into the Company in 2004. The Company acquired Merrifield Pharma Private Limited in 2006. Later, the Company opened new areas of biology facility in Watertown (Greater Boston, MA) U.S.A. for innovative and creative smallmolecule drugs in 2019. It launched Sai Nxt, an initiative to transform the organization into a new generation CDMO in 2020. It further added cellular analysis platforms at its discovery biology facility in Cambridge, Massachusetts, USA.In 2021, the Company opened a new discovery biology facility at Unit II Plant in Hyderabad. In 2022, it opened the first set of new disconvery chemistry labs at Unit III Plant, Hyderabad. In 2023, the Company opened high potency API manufacturing block at Unit IV Bidar Facility and has launched a dedicated Peptide Research Center at Unit II at Hyderabad in FY 2025. The Company raised funds aggregating Rs 3042.6 Crore by issuing 55,421,123 equity shares of face value of Re 1 each, comprising a fresh issue of 17,304,189 equity shares amounting to Rs 950 Cr and 38,116,934 equity shares amounting to Rs 2092.62 Cr in December 2024.

For the full year FY2026–2027, revenue reached ₹2241.62 crore and profit touched at ₹348.91 crore. As of Mar '26, Sai Life Sciences’s market capitalisation stood at ₹24,605.40 crores. Shareholding as of Mar '26 shows promoters holding 34.6%, with FIIs at 21.2%, DIIs at 31.5%, and public at 12.7%.